|
KMID : 1035620150030040294
|
|
Allergy Asthma & Respiratory Disease
2015 Volume.3 No. 4 p.294 ~ p.296
|
|
|
Successful rapid desensitization for cetuximab-induced anaphylaxis
|
|
원하경:Won Ha-Kyeong
문성도:Moon Sung-Do/심지수:Shim Ji-Su/정수지:Chung Soo-jie/김건우:Kim Gun-Woo/김수정:Kim Su-Jeong/박한기:Park Han-Ki/강혜련:Kang Hye-Ryun
|
|
|
Abstract
|
|
|
|
Cetuximab, a chimeric mouse-human immunoglobulin, is an antiepidermal growth factor receptor monoclonal antibody. It has been approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal and head/neck cancer, but can cause fatal hypersensitivity reactions in some patients. A 66-year-old male with metastatic sigmoid cancer had cetuximab-induced anaphylaxis when the first dose of cetuximab was administered. Cetuximab was safely readministered for another 15 cycles based on the rapid desensitization protocol. We experienced a case of cetuximab-induced anaphylaxis on the first exposure which was successfully managed by rapid desensitization.
|
|
|
KEYWORD
|
|
|
Cetuximab, Hypersensitivity, Immunologic desensitization
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
 
|